汇宇制药(688553)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688553 汇宇制药

已收盘 11-04 15:00:00

{"stockData":{"symbol":"688553","market":"SH","secType":"STK","nameCN":"汇宇制药","latestPrice":16.1,"timestamp":1730703600000,"preClose":16.48,"halted":0,"volume":14820907,"delay":0,"floatShares":310000000,"shares":424000000,"eps":0.6568,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.38,"latestTime":"11-04 15:00:00","open":16.67,"high":17.31,"low":15.93,"amount":246000000,"amplitude":0.0837,"askPrice":16.11,"askSize":12,"bidPrice":16.1,"bidSize":95,"shortable":0,"etf":0,"ttmEps":0.6568,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1730770200000},"adr":0,"adjPreClose":16.48,"symbolType":"stock_kcb","openAndCloseTimeList":[[1730683800000,1730691000000],[1730696400000,1730703600000]],"highLimit":18.13,"lowLimit":14.83,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":423600000,"pbRate":1.76,"roa":"--","roe":"5.92%","epsLYR":0.33,"committee":0.607692,"marketValue":6820000000,"floatMarketCap":4983000000,"peRate":24.51279,"changeRate":-0.0231,"turnoverRate":0.0479,"status":1,"afterMarket":{"amount":0,"volume":0,"close":16.1,"buyVolume":0,"sellVolume":0,"time":1730705639464,"indexStatus":"已收盘 11-04 15:30:00","preClose":16.48}},"requestUrl":"/m/hq/s/688553","defaultTab":"news","newsList":[{"id":"2480459740","title":"汇宇制药-W大幅上涨 获主力净流入927万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480459740","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480459740?lang=zh_cn&edition=full","pubTime":"2024-11-01 11:12","pubTimestamp":1730430742,"startTime":"0","endTime":"0","summary":"11月01日，汇宇制药-W股价大幅上涨，截至11点12分，汇宇制药-W上涨5.01%，报16.34元/股，成交1.22亿元，换手率2.50%，振幅5.46%。资金动向截止发稿，汇宇制药-W获得主力净流入927万元，其中超大单流入1127万元，大单流出199万元。融资融券方面，汇宇制药-W10月30日获得融资净买入1138万元，当日该股融资余额为1.67亿元，当较前一日增加7.33%。主营业务及业绩汇宇制药-W公司主营业务为肿瘤领域药物和复杂注射剂药物的研发、生产和国内外销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101111228a205d700&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101111228a205d700&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2479759102","title":"10月30日汇宇制药现1996.65万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2479759102","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479759102?lang=zh_cn&edition=full","pubTime":"2024-10-30 17:45","pubTimestamp":1730281546,"startTime":"0","endTime":"0","summary":"证券之星消息，10月30日汇宇制药发生大宗交易，交易数据如下：大宗交易成交价格14.79元，相对当日收盘价折价3.02%，成交135万股，成交金额1996.65万元，买方营业部为国信证券股份有限公司福建分公司，卖方营业部为国盛证券有限责任公司南昌金融大街证券营业部。近三个月该股共发生5笔大宗交易，合计成交22.5万手，折价成交3笔，溢价成交2笔。截至2024年10月30日收盘，汇宇制药报收于15.25元，下跌3.11%，换手率4.14%，成交量12.8万手，成交额1.96亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000034467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2479982292","title":"【机构调研记录】申万菱信基金调研汇宇制药、健康元等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2479982292","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479982292?lang=zh_cn&edition=full","pubTime":"2024-10-30 08:06","pubTimestamp":1730246782,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及10月29日披露的机构调研信息，申万菱信基金近期对3家上市公司进行了调研，相关名单如下：1）汇宇制药 个股亮点：公司积极推进肿瘤治疗领域生物创新药和小分子创新药的研发。2）健康元 个股亮点：公司GDR已经于2022-09-26成功上市。申万菱信基金成立于2004年，截至目前，资产管理规模906.03亿元，排名64/207；资产管理规模791.33亿元，排名54/207；管理公募基金数143只，排名48/207；旗下公募基金经理27人，排名47/207。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000009130.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","600380","BK0239","688553","BK0077","BK0046","BK0188","BK0028"],"gpt_icon":0},{"id":"2479298756","title":"【机构调研记录】德邦基金调研汇宇制药、芯动联科等8只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2479298756","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479298756?lang=zh_cn&edition=full","pubTime":"2024-10-30 08:05","pubTimestamp":1730246729,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及10月29日披露的机构调研信息，德邦基金近期对8家上市公司进行了调研，相关名单如下：1）汇宇制药 个股亮点：公司积极推进肿瘤治疗领域生物创新药和小分子创新药的研发。2）芯动联科 个股亮点：公司向低空经济领域客户提供技术方案、测试方案并进行质量控制体系认证；公司产品可用于无人驾驶和机器人领域。6）恒玄科技 个股亮点：公司主营产品包括TWS耳机芯片。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000009093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688582","688553","BK0214"],"gpt_icon":0},{"id":"2479590475","title":"汇宇制药：10月28日接受机构调研，北京橡果资产管理有限公司、北京信伟达资产管理有限公司等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2479590475","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479590475?lang=zh_cn&edition=full","pubTime":"2024-10-29 17:42","pubTimestamp":1730194966,"startTime":"0","endTime":"0","summary":"注射用紫杉醇2023 年在全球销售额超 25 亿美元，公司已在部分欧洲及新兴市场 进行申报。蔗糖铁注射液、戈舍瑞林植入剂目前在进行 BE 试验。公司将持续推进上述复杂注射剂的注册和上市，为未来成长奠定基础。欧洲和美国市场竞 争比较激烈，且周期长。欧洲公司已上市 22 款产品，美国市场已有多 西他赛、环磷酰胺两款产品上市。一方面为计入 当期损益的持有金融资产产生的公允价值增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900033945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09983","BK1542","688553","BK1258","BK0239","BK1229","BK1583"],"gpt_icon":0},{"id":"2478389433","title":"汇宇制药涨停 营业部龙虎榜净买入152.45万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2478389433","media":"证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478389433?lang=zh_cn&edition=full","pubTime":"2024-10-28 22:36","pubTimestamp":1730126160,"startTime":"0","endTime":"0","summary":"证券时报网讯，10月28日汇宇制药（688553）收盘价15.82元，收盘涨停，全天换手率6.48%，振幅11.02%，成交额3.06亿元。科创板交易公开信息显示，当日该股因日收盘价涨幅达15%等上榜。证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交7693.54万元， 其中，买入成交额为3923.00万元，卖出成交额为3770.55万元，合计净买入152.45万元。（文章来源：证券时报网）\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2024-10-28/doc-incucrwq2532434.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-10-28/doc-incucrwq2532434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2478848180","title":"四川A股134家上涨 汇宇制药领涨川润股份九连板","url":"https://stock-news.laohu8.com/highlight/detail?id=2478848180","media":"上游新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478848180?lang=zh_cn&edition=full","pubTime":"2024-10-28 21:25","pubTimestamp":1730121917,"startTime":"0","endTime":"0","summary":"2024年10月28日，176家四川A股上市公司中有134家上涨。涨停的川股共12家，除科创板的汇宇制药外，莱茵体育、国机重装、成都路桥、四川长虹、四川双马、川润股份、川发龙蟒、川大智胜、旭光电子、华神科技10家主板也涨停，ST广物涨停。川润股份为九连板。10月28日，川润股份上涨10.01%，报收13.96元，收盘价创历史新高，迎来连续第九个涨停，换手率20.84%，成交量79.11万手，成交额10.70亿，总市值67.69亿元，9个交易日累计上涨135.92 %，今年以来涨幅累计105.60%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028213851ab7bc7cf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028213851ab7bc7cf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159982","BK0259","399300","BK0239","002272","688553"],"gpt_icon":0},{"id":"2478474301","title":"异动快报：汇宇制药-W（688553）10月28日13点0分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2478474301","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478474301?lang=zh_cn&edition=full","pubTime":"2024-10-28 13:05","pubTimestamp":1730091934,"startTime":"0","endTime":"0","summary":"证券之星10月28日盘中消息，13点0分汇宇制药-W（688553）触及涨停板。目前价格15.82，上涨20.03%。其所属行业化学制药目前上涨。领涨股为亨迪药业。该股为创新药，医药概念热股，当日创新药概念上涨2.36%，医药概念上涨2.25%。10月28日的资金流向数据方面，主力资金净流入562.49万元，占总成交额2.46%，游资资金净流出1398.53万元，占总成交额6.13%，散户资金净流入836.04万元，占总成交额3.66%。近5日资金流向一览见下表：汇宇制药-W主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800012172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2478112893","title":"汇宇制药-W大幅上涨 获主力净流出172万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2478112893","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478112893?lang=zh_cn&edition=full","pubTime":"2024-10-28 09:30","pubTimestamp":1730079001,"startTime":"0","endTime":"0","summary":"10月28日，汇宇制药-W股价大幅上涨，截至09点30分，汇宇制药-W上涨9.71%，报14.46元/股，成交795万元，换手率0.18%，振幅1.21%。资金动向截止发稿，汇宇制药-W获得主力净流出172万元，其中超大单流入74万元，大单流出246万元。主营业务及业绩汇宇制药-W公司主营业务为肿瘤领域药物和复杂注射剂药物的研发、生产和国内外销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028093251a1f01d9e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028093251a1f01d9e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2478811327","title":"汇宇制药（688553）1839.79万股限售股将于10月28日解禁，占总股本4.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478811327","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478811327?lang=zh_cn&edition=full","pubTime":"2024-10-28 08:03","pubTimestamp":1730073799,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，汇宇制药于10月28日将有1839.79万股限售股份解禁，为公司首发原股东限售股份，占公司总股本4.34%。本次解禁后，公司还有1.14亿股限售股份，占总股本26.93%。汇宇制药主营业务：从事肿瘤治疗领域创新药和优质仿制药的研发、生产和国内外销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800001219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2478670127","title":"汇宇制药(688553.SH)发布前三季度业绩，净利润2.27亿元，同比增长155.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478670127","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478670127?lang=zh_cn&edition=full","pubTime":"2024-10-25 16:46","pubTimestamp":1729845999,"startTime":"0","endTime":"0","summary":"智通财经APP讯，汇宇制药(688553.SH)披露2024年第三季度报告，公司前三季度实现营收8.52亿元，同比增长29.24%;归母净利润2.27亿元，同比增长155.62%;扣非净利润1亿元，同比增长141.81%;基本每股收益0.54元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1199797.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688553"],"gpt_icon":0},{"id":"2477635448","title":"治疗晚期实体瘤！成都汇宇制药HY07121生物药I期临床试验首例受试者给药成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2477635448","media":"红星新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477635448?lang=zh_cn&edition=full","pubTime":"2024-10-24 20:54","pubTimestamp":1729774440,"startTime":"0","endTime":"0","summary":"微成都报道10月24日晚间，汇宇制药全资子公司四川汇宇海玥医药科技有限公司首个自主研发的1类生物创新药注射用HY07121正在开展用于治疗晚期实体瘤的I期临床试验，于近日成功完成首例受试者给药。注射用HY07121在获得国家药品监督管理局的药物临床试验批准后，根据国内创新型生物制品相关指导原则，启动“一项评价注射用 HY07121在晚期恶性实体瘤患者中的安全性、耐受性、药代动力学特征和初步临床有效性的多中心、开放的 I/II 期临床研究”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241024205508a1e71a75&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241024205508a1e71a75&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","159839","688553"],"gpt_icon":0},{"id":"2477509992","title":"汇宇制药(688553.SH)：生物创新药注射用HY07121I期临床试验首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2477509992","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477509992?lang=zh_cn&edition=full","pubTime":"2024-10-24 17:35","pubTimestamp":1729762506,"startTime":"0","endTime":"0","summary":"智通财经APP讯，汇宇制药(688553.SH)发布公告，公司全资子公司四川汇宇海玥医药科技有限公司(以下简称“汇宇海玥”)首个自主研发的1类生物创新药注射用HY07121(项目研发代号为“HY-0007”)正在开展用于治疗晚期实体瘤的I期临床试验，于近日成功完成首例受试者给药。注射用HY07121一方面可以补充免疫细胞来源，增加瘤内效应细胞的数量;另一方面可以从多角度将因持续战斗而耗竭的免疫细胞恢复功能，从而不但加强了免疫疗效，并且克服部分免疫治疗患者获得性耐药问题。HY07121是一款协同潜力优秀，具备增强肿瘤免疫治疗疗效及克服免疫耐药的一类创新药，预期为晚期肿瘤患者提供新的治疗选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1198904.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","688553","BK0239","BK1161","BK1583","BK1141","BK1574","BK1576","03347","159992"],"gpt_icon":0},{"id":"2477501870","title":"【市场】6亿注射剂，汇宇制药首家过评","url":"https://stock-news.laohu8.com/highlight/detail?id=2477501870","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477501870?lang=zh_cn&edition=full","pubTime":"2024-10-24 17:09","pubTimestamp":1729760982,"startTime":"0","endTime":"0","summary":"精彩内容近日，汇宇制药公告称，公司以仿制3类报产的乙酰半胱氨酸注射液获批上市，为国内首家过评。乙酰半胱氨酸注射液适应症为急性对乙酰氨基酚中毒解毒，用于预防或减轻其过量引起的肝脏损伤。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241024174435ab70092f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241024174435ab70092f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2477381388","title":"汇宇制药(688553.SH)：乙酰半胱氨酸注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2477381388","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477381388?lang=zh_cn&edition=full","pubTime":"2024-10-22 17:24","pubTimestamp":1729589060,"startTime":"0","endTime":"0","summary":"智通财经APP讯，汇宇制药(688553.SH)发布公告，公司于近日收到国家药品监督管理局核准签发的乙酰半胱氨酸注射液《药品注册证书》，乙酰半胱氨酸注射液适应症为急性对乙酰氨基酚中毒解毒，用于预防或减轻其过量引起的肝脏损伤。公司获批的乙酰半胱氨酸注射液注册分类为化学药品3类，按照与参比制剂质量和疗效一致的技术要求审评并获批，批准后视同通过仿制药质量和疗效一致性评价。根据国家相关政策，通过一致性评价的药品品种在医保支付及医疗机构采购等领域将获得更大的支持力度。公司研发的乙酰半胱氨酸注射液通过仿制药一致性评价，提升了自身的竞争能力，对公司的发展起到积极作用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1197440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2477888303","title":"10月22日汇宇制药现8108.8万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2477888303","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477888303?lang=zh_cn&edition=full","pubTime":"2024-10-22 17:20","pubTimestamp":1729588840,"startTime":"0","endTime":"0","summary":"证券之星消息，10月22日汇宇制药发生大宗交易，交易数据如下：大宗交易成交价格12.67元，相对当日收盘价溢价1.04%，成交640万股，成交金额8108.8万元，买方营业部为国盛证券有限责任公司南昌金融大街证券营业部，卖方营业部为兴业证券股份有限公司南昌洪城路证券营业部。截至2024年10月22日收盘，汇宇制药报收于12.54元，上涨1.05%，换手率1.23%，成交量3.57万手，成交额4475.31万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102200028866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2477131383","title":"汇宇制药： 产品取得注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2477131383","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477131383?lang=zh_cn&edition=full","pubTime":"2024-10-22 17:18","pubTimestamp":1729588703,"startTime":"0","endTime":"0","summary":"每经AI快讯，汇宇制药（SH 688553，收盘价：12.54元）10月22日晚间发布公告称，四川汇宇制药股份有限公司于近日收到国家药品监督管理局核准签发的《药品注册证书》。产品名称为“乙酰半胱氨酸注射液”。2023年1至12月份，汇宇制药的营业收入构成为：医药占比99.89%。截至发稿，汇宇制药市值为53亿元。道达号（daoda1997）“个股趋势”提醒：1. 近30日内无机构对汇宇制药-W进行调研。每经头条（nbdtoutiao）——A股利好！百亿元大消息，火速落地！涉及23家公司，深度解析→(记者 曾健辉)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410221718539f563234&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410221718539f563234&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2476382612","title":"汇宇制药：18397865股限售股将于10月28日上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2476382612","media":"证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476382612?lang=zh_cn&edition=full","pubTime":"2024-10-18 19:39","pubTimestamp":1729251540,"startTime":"0","endTime":"0","summary":"证券日报网讯10月18日晚间，汇宇制药发布首次公开发行部分限售股上市流通公告称，本次股票上市类型为公司首发限售股份；股票认购方式为网下，本次股票上市流通总数为18，397，865股。本次股票上市流通日期为2024年10月28日。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2024-10-18/doc-incsysht5277437.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-10-18/doc-incsysht5277437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2476440131","title":"汇宇制药：员工持股平台承诺6个月内不减持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2476440131","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476440131?lang=zh_cn&edition=full","pubTime":"2024-10-18 17:30","pubTimestamp":1729243826,"startTime":"0","endTime":"0","summary":"汇宇制药公告，公司员工持股平台内江衡策和内江盛煜分别持有公司股份11,038,719股和7,359,146股，合计占公司总股本的4.35%。基于对公司未来发展前景的信心及长期投资价值的认可，这两个员工持股平台自愿承诺自2024年10月28日起未来6个月内不以任何方式减持其所持有的公司股份。在上述承诺期间内，因公司送红股、转增股本、配股等原因而增加的股份，亦遵守上述不减持的承诺。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101800030772.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2476406646","title":"汇宇制药：员工持股平台承诺6个月内不减持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2476406646","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476406646?lang=zh_cn&edition=full","pubTime":"2024-10-18 17:19","pubTimestamp":1729243149,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0239","688553"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-10-26","address":"四川省内江市市中区汉阳路333号3幢","stockEarnings":[{"period":"1week","weight":0.0177},{"period":"1month","weight":0.2413},{"period":"3month","weight":0.3586},{"period":"6month","weight":0.1161},{"period":"1year","weight":0.1018},{"period":"ytd","weight":0.0815}],"companyName":"四川汇宇制药股份有限公司","boardCode":"AI0027","perCapita":"18693股","boardName":"医药制造业","registeredCapital":"42360万元","compareEarnings":[{"period":"1week","weight":-0.0036},{"period":"1month","weight":-0.0079},{"period":"3month","weight":0.1545},{"period":"6month","weight":0.0581},{"period":"1year","weight":0.0922},{"period":"ytd","weight":0.1127}],"survey":"　　四川汇宇制药股份有限公司主营业务为肿瘤治疗领域药物和复杂注射剂药物的研发、生产和国内外销售。主要产品有原料药、抗肿瘤注射剂、肿瘤辅助用药、造影剂等。公司荣登“2022年四川省新经济100强企业榜单”；荣获“四川省2022年度科技创新引才引智先进基地”；荣获“2023年中国医药新锐创新力量”；荣获“四川企业技术创新发展能力100强”且名次跃升至第6位；再次斩获“四川企业技术创新发展最具潜力20强企业”；荣获“2023年度科技人才工作先进单位”表彰授牌。","serverTime":1730755476987,"listedPrice":38.87,"stockholders":"16558人(较上一季度减少3.20%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"汇宇制药(688553)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供汇宇制药(688553)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"汇宇制药,688553,汇宇制药股票,汇宇制药股票老虎,汇宇制药股票老虎国际,汇宇制药行情,汇宇制药股票行情,汇宇制药股价,汇宇制药股市,汇宇制药股票价格,汇宇制药股票交易,汇宇制药股票购买,汇宇制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"汇宇制药(688553)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供汇宇制药(688553)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}